This PPT comprises of brief history of vaccines and its details, concentrated on adverse reactions due to various vaccines, and briefly bout the cold chain.
Understanding the Medical device Single Audit Program (MDSAP) & How to Prepar...Greenlight Guru
The Medical Device Single Audit Program (MDSAP) is an international initiative spearheaded by the International Medical Device Regulatory Forum (IMDRF) to develop a standardized global approach to auditing and inspecting of medical device manufacturers that will be accepted by multiple regulators to address QMS/GMP requirements.
Although the program has seen relatively low participation to date, the promise to help reduce compliance cost for device makers by eliminating the need for multiple quality system audits and inspections means there is much to be gained by industry from a successful implementation the program.
This presentation will cover:
-Understand the goals and benefits of the MDSAP program
-What are the main differences between MDSAP and standard auditing
-How to benchmark your QMS against the MDSAP
-How the new non-conformance grading system works
-How to prepare your company for a successful MDSAP implementation
Watch the presentation here: https://www.greenlight.guru/webinar/medical-device-single-audit-program-mdsap
Overview on “Computer System Validation” CSVAnil Sharma
HI this is Anil Sharma, Executive Compliance in USV LTD. I want to share my brief knowledge on CSV with you. I hope my presentation will help you to understand basics of CSV.
This PPT comprises of brief history of vaccines and its details, concentrated on adverse reactions due to various vaccines, and briefly bout the cold chain.
Understanding the Medical device Single Audit Program (MDSAP) & How to Prepar...Greenlight Guru
The Medical Device Single Audit Program (MDSAP) is an international initiative spearheaded by the International Medical Device Regulatory Forum (IMDRF) to develop a standardized global approach to auditing and inspecting of medical device manufacturers that will be accepted by multiple regulators to address QMS/GMP requirements.
Although the program has seen relatively low participation to date, the promise to help reduce compliance cost for device makers by eliminating the need for multiple quality system audits and inspections means there is much to be gained by industry from a successful implementation the program.
This presentation will cover:
-Understand the goals and benefits of the MDSAP program
-What are the main differences between MDSAP and standard auditing
-How to benchmark your QMS against the MDSAP
-How the new non-conformance grading system works
-How to prepare your company for a successful MDSAP implementation
Watch the presentation here: https://www.greenlight.guru/webinar/medical-device-single-audit-program-mdsap
Overview on “Computer System Validation” CSVAnil Sharma
HI this is Anil Sharma, Executive Compliance in USV LTD. I want to share my brief knowledge on CSV with you. I hope my presentation will help you to understand basics of CSV.
Many thanks to Government of India, PATH, WHO, Immunization Basics for the slides. Comments from diseasesurveillance and mfriendcircle yahoogroup members helped to refine the presentation. It is also going to the Technet 21 group
Corrective Actions and Preventive Actions.Corrective Action Preventive Action (CAPA) is a process which investigates and solves problems, identifies causes, takes corrective action and prevents recurrence of the root causes. The ultimate purpose of CAPA is to assure the problem can never be experienced again. Corrective vs. Preventive Action. Quality professionals frequently express confusion as to the difference between corrective and preventive action. A corrective action deals with a nonconformity that has occurred, and a preventive action addresses the potential for a nonconformity to occur.
Presentation: Medical Devices Single Audit Program (MDSAP) Pilot ProgramTGA Australia
This presentation provides an update on the progress of the Pilot and explores how the results of audits will be used by the participating Regulatory Authorities in support of market authorisation within their jurisdictions.
Province 1 envisaged to develop Ayurveda Management Information System in three phase. The two phases have already been completed. Here is the presentation on the Ayurveda Management Information System Tools and Ayurveda Management information System Indicators.
This presentation consist of what ISO 14971 is and why is it important to consider this standard while designing a medical device or any device for that matter. It will help u understand what Risk actual is and importance of risk management in medical device industry. It gives you insight about Risk management technique. You will Understand FMEA and how to use it.
Many thanks to Government of India, PATH, WHO, Immunization Basics for the slides. Comments from diseasesurveillance and mfriendcircle yahoogroup members helped to refine the presentation. It is also going to the Technet 21 group
Corrective Actions and Preventive Actions.Corrective Action Preventive Action (CAPA) is a process which investigates and solves problems, identifies causes, takes corrective action and prevents recurrence of the root causes. The ultimate purpose of CAPA is to assure the problem can never be experienced again. Corrective vs. Preventive Action. Quality professionals frequently express confusion as to the difference between corrective and preventive action. A corrective action deals with a nonconformity that has occurred, and a preventive action addresses the potential for a nonconformity to occur.
Presentation: Medical Devices Single Audit Program (MDSAP) Pilot ProgramTGA Australia
This presentation provides an update on the progress of the Pilot and explores how the results of audits will be used by the participating Regulatory Authorities in support of market authorisation within their jurisdictions.
Province 1 envisaged to develop Ayurveda Management Information System in three phase. The two phases have already been completed. Here is the presentation on the Ayurveda Management Information System Tools and Ayurveda Management information System Indicators.
This presentation consist of what ISO 14971 is and why is it important to consider this standard while designing a medical device or any device for that matter. It will help u understand what Risk actual is and importance of risk management in medical device industry. It gives you insight about Risk management technique. You will Understand FMEA and how to use it.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
2. A.E.F.I.
Why “event” – not “effect”?
Event -vs- Effect (outcome of RI)
Not desired desired /expected
Unwanted wanted
Eventful uneventful
Warrants does not
actions warrant actions
More players Less players
(people gets involved) (only beneficiary involved)
3. AEFI is defined as: |
nt s
A medical event that takes place ka s
er g
| K | En
| me
ala age
after an immunization, causes h|
rn ataneou
Ka cella
es | Mis er
nd n
concern and is believed to be ra d rt u i
r
pe hr a P| Spo am tion es
pa nd ess l te a l
e ws A in ve ccin eas last
e a m y
lN u| s h- l v
caused by immunization
l
o na ad | Bu iona hig sles ll at aFrida
at i il N n at a a i
N am pinio y | N ted me ken sil on
ia's |T pu g a
nd 008 ersio
n
al al | O itua
r de owin six t ri teh
fI on b as l l d b
n o30, 2DA V ati ations | O t h t s fo d an l am
io
dit ep le/P |N n b en n e u
e S i g e I n t e r | Jo
a | o n: nm infa d di in Ph
r r
ati
ne , e
nli sday | Mo
b tP ds ov u h a e
O e Fr on tates sifie in l g of foants centr
r
Tu ape al r | er S Clas cc tr a f
e th | a en eathur in alth
It is important that AEFIs are detected,
eP tion Pap O us
a s: e hi | l Pl
N w e l ai
e D et
n
wi anga
g V bad I:
e C d o he
Th e theek. F ary
LH tigat t we prim
lo r DE s
fol or Au
N ew : R s n
W invetra laudea
investigated, monitored and promptly
N vts
Ad
ath ams
s f NE to h J
nt eral aras the
4 obde e te de
on -Gen Mahed a
t
responded to for corrective interventions.
Pr
lC
esp or of is
orr irect trict rgan
is o
e cia cial D d d mp
Sp Spe gaba n ca
a ran atio
u in
4. Types of AEFIs
• Program Errors
• Vaccine reactions
• Coincidental
• Injection reaction
• Unknown
5. Types of AEFI
1. Programmatic Error
• Due to error in vaccine preparation, handling or administration.
• Majority of AEFIs occur due to programmatic errors
– and preventable
Non-sterile needle
Suppurative Lymphadenitis
following BCG Vaccination
6. Common programmatic errors
which can lead to AEFIs
Non-sterile injection
Contact of needle with unsterile surface
e.g. finger, swab, table etc.
Infection can manifest as:
Administering injection over clothes
Local reactionvaccine or diluent abscess
Contaminated – suppuration,
Use of reconstituted vaccines beyond
Systemic effecthours
the stipulated 4
– sepsis, toxic shock syndrome
Blood borne virus infection at HIV, HBV, HCV
Reuse of reconstituted vaccine –
subsequent sessions
Reuse of disposable syringe & needle
Time ??
7. Common programmatic errors
which can lead to AEFIs
Reconstitution error/ Wrong vaccine preparation
Reconstitution with incorrect diluent
- less vaccine effectiveness
Drug substituted for diluent – drug reaction, death
Inadequate shaking of T-series vaccines
– local abscess
Injection at incorrect site/route
Injection into gluteal region (buttocks)
– sciatic nerve damage
BCG /T series vaccine given subcutaneously
– local reaction or abscess
8. Common programmatic errors
which can lead to AEFIs
Vaccine transportation/storage incorrect
Administration of frozen and thawed
freeze-sensitive vaccine -local reaction
such as sterile abscess
Contraindications ignored
DPT2 given after H/O convulsions with DPT1
- convulsions
9. Common program errors can be prevented by :-
• training of H.W.
• regular supervision
• adequate supply / availability of logistics
10. …Types of AEFI
2. Vaccine Reaction
An event caused or precipitated by the active component or
one of the other components of the vaccine (e.g. adjuvant,
preservative or stabilizer).
This is due to the inherent properties of the vaccine.
A. Common, minor vaccine reactions
– local reaction (e.g. pain, swelling and/or redness, fever).
- Local reactions and fever should be anticipated in only 10% of the vaccine
recipients, except in the case of whole cell DPT which produces fever in
nearly half of those vaccinated.
11. …Types of AEFI
2. Vaccine Reaction
- Fever and minor local and systemic reactions usually occur within a day or
two of immunization (except for those produced by measles/MMR vaccine
which occurs 6 to 12 days after immunization) and only last for few days.
- Fever and minor local reactions can usually be treated symptomatically with
paracetamol.
- systemic symptoms (e.g. vomiting, diarrhoea, malaise)
B. Rare serious vaccine reactions
High (39-40.4oC / 102-104.7oF) to extreme fevers (>40.5oC/105 oF)
indicate the possibility of:
Anaphylaxis - potentially fatal allergic reaction, but treatable
12. …Types of AEFI
3. Coincidental Event
An event that occurs after immunization but is not caused by the vaccine.
This is due to a chance temporal association
Example: pneumonia after oral polio vaccine administration
4. Injection Reaction
Event caused by anxiety about, or pain from the injection
itself rather than the vaccine
Example: fainting spell in a teenager after vaccination
5. Unknown
Any event due to undetermined cause.
13. Interval No. of
AEFI Vaccine Definition between events / Treatment
vaccn. & million
onset doses
Heals spontaneously
Either at least one lymph 2 to 6 over months and best
nodes enlarged to >1.5 cm in months not to treat. If lesion is
size (one adult finger width) or after sticking to skin or
a draining sinus over a lymph receipt of already draining,
Suppurative BCG node. BCG 100-1000 surgical drainage and
lymphadenitis vaccine
Almost exclusively caused by local instillation of anti-
BCG - same side as tuberculosis drug.
inoculation (mostly axillary). Systemic treatment with
anti-tuberculous drugs is
ineffective
Acute onset of major illness
characterized by any two of Within 48
the following three conditions: hours of No specific treatment
seizures DPT or available;
Encephalopath Measles, -
severe alteration in level of from 7 to supportive care.
y Pertussis
consciousness lasting for 12 days
after
one day or more
measles
Distinct change in behavior vaccine
lasting one day or more..
Persistent DPT, Inconsolable continuous 0-48 1,000- Settles within a day or
inconsolable Pertussis crying lasting 3 hours or hours 60,000 so; analgesics may help.
longer accompanied by high-
screaming
pitched screaming.
14. Interval No. of
AEFI Vaccine Definition between events / Treatment
vaccn. & million
onset doses
Seizures Occurrence of generalized
are mostly convulsions that are not
febrile in origin, accompanied by focal
the rate All, neurological signs or Self-limiting; supportive
depends on symptoms.
especially care; paracetamol and
past history, Febrile seizures: if cooling if febrile; rarely
family history Pertussis, 0-3 days 600
temperature elevated anticonvulsants.
and age, much Measles >100.4 0F or 38 0C (rectal)
lower risk in
infants < age of Afebrile seizures: if
4 mns. temperature is normal
15. AEFIs following ALL injectible vaccines
AEFI Definition Treatment
The fever can be classified (based on rectal Symptomatic; paracetamol.
temperature) such as Give extra oral fluids.
Mild fever: 100.4 0F to 102 0F (38 to 38.9 0C), Tepid sponge or bath.
Fever High fever: 102 0F to 104.7 0F (39 to 40.40C) and In cases of high and extreme fever, other
Extreme fever: 104.7 0F or higher (>40.50C). signs and symptoms should be sought
and reported /managed as appropriate.
Fluctuant or draining fluid-filled lesion at injection.
Injection Bacterial if evidence of infection (e.g. purulent,
site inflammatory signs, fever, culture), Sterile abscess if Incise and drain; Antibiotics if bacterial.
abscess no evidence of bacterial infection on culture. Sterile
abscesses are usually due to the inherent properties
of the vaccine.
Acute onset of severe generalized illness due to Critical to recognize and treat early.
Sepsis bacterial infection and confirmed (if possible) by Urgent hospitalization
positive blood culture. Needs to be reported as for intravenous antibiotics and fluids
possible indicator of program error.
Redness and/or swelling centered at the site of
Severe injection and one or more of the following: Settles spontaneously within a few days
local Swelling beyond the nearest joint to a week. Symptomatic treatment with
reaction Pain, redness, and swelling of more than 3 days analgesics.
Requires hospitalization. Antibiotics are inappropriate.
Local reactions of lesser intensity occur commonly
and are trivial and do not need to be reported.
16. AEFIs following ALL injectible vaccines
AEFI Definition Treatment
Toxic shock Abrupt onset of fever, vomiting and watery diarrhoea Critical to recognize and treat early.
syndrome within a few hours of immunization. Often leading to Urgent hospitalization for intravenous
(TSS) death within 24 to 48 hours. Report as a possible antibiotics and fluids
indicator of program error.
Anaphylactoid Exaggerated acute allergic reaction, occurring Self-limiting
reaction (acute within 2 hours after immunization, characterized by Anti-histamines may be useful
one or more of the following:
hypersensitivity
reaction) wheezing and shortness of breath due to
bronchospasm
Laryngospasm / laryngeal oedema
One or more skin manifestations, e.g. hives, facial
oedema, or generalized oedema.
Do not report less severe allergic reactions
Severe immediate (within 5-30 minutes) allergic Most life-threatening reactions begin
reaction leading to circulatory failure with or without within 10 minutes of immunization.
bronchospasm and / or laryngospasm / laryngeal Keep the vaccinee under
oedema observation
The early signs of anaphylaxis are generalized for at least 20 minutes after the
erythema and urticaria with upper and/or lower injection.
Anaphylaxis respiratory tract obstruction. Transfer the patient swiftly to
In more severe cases, limpness, pallor, loss of hospital
consciousness and hypotension become evident in Make sure the details accompany the
addition. patient when he is transferred. Mark
A strong central pulse (e.g. carotid) is maintained the immunization card clearly so the
during a faint, but not in anaphylaxis. individual never gets a repeat dose
of the offending vaccine
17. Treatment of Anaphylaxis
Adrenaline (epinephrine) counters anaphylaxis.
Keep emergency kit ready with adrenaline. kit should be checked three or four times a year. Adrenaline
that has a brown tinge must be discarded.
Ensure the airway is clear. If appropriate, begin cardiopulmonary resuscitation.
Give 1:1000 adrenaline at a dose of 0.01ml/kg up to a maximum of 0.5 ml by deep intramuscular
injection into the opposite limb to that in which the vaccine was given. (Subcutaneous administration is
acceptable in mild cases).
If the weight of the patient is unknown, an approximate guide is:
Less than 2 years 2-5 years 6-11 years 11+ years
0.0625 ml (1/16th of a ml) 0.125 ml (1/8th of a ml) 0.25 ml (1/4 of a ml) 0.5 ml (1/2 of a ml)
And give an additional half dose around the injection site (to delay antigen absorption).
If the patient is conscious after the adrenaline is given, place his/her head lower than the feet and keep the
patient warm.
Give oxygen by face mask.
Call an ambulance (or arrange other means of transport, after the first injection of adrenaline. If there is no
improvement within 10-20 minutes, of the first injection, repeat the dose of adrenaline up to a maximum of
three doses in total. Recovery from anaphylactic shock is usually rapid after adrenaline.
At a suitable moment, explain to parents or relatives the importance of avoiding the vaccine in the future.
18. Reporting AEFIs
Why report AEFIs ?
• Effective means of monitoring immunization
safety
• Contributes to quality & credibility of program
• Helps in clinical management of case
• Identify gaps in program implementation (if any)
• Helps identify actual rate of occurrence.
• Avoids false rumors
• Build confidence of public in program
19. Cluster of AEFIs
A cluster is defined as two or more cases of the same or
similar events, which are related in time, and have occurred
within specific geographical area, or associated with the
same vaccine, the same batch number or the same
vaccinator.
e.g. two or more cases of abscess occur in a village following an
immunization session
Or
multiple abscess cases following immunization by the same vaccinator or
the same batch of the vaccine, but in different villages.
20. Reporting of AEFIs
What to report How to report Who reports to Whom When to report
For Immediate Reporting Telephone or HWs MO DIO/CMO Immediately
and Investigation – any other quick SIO
SERIOUS AEFIs means of
communication
Death FIR (First Information Report) Within 24 hrs
Hospitalization (anaphylaxis, to District &
anaphylactoid reaction, TSS, 48 hrs to State
Encephalopathy, Sepsis) PIR and GOI
Any event where vaccine (Preliminary Investigation
quality is suspected Report) Within 7 days
Events occurring in a cluster
DIR
Within 90 days
(Detailed Investigation report)
For Routine Monthly reporting
Deaths
Injection site abscesses
Persistent (> 3hrs) screaming
HHE
UIP Report HWs MO DIO/CMO
Severe local reaction
Seizures including febrile seizures SIO Monthly
Brachial neuritis
Thrombocytopenia
Lymphadenitis All reported cases that are not
Disseminated BCG infection serious are recorded as minor
Osteitis / Osteomyelitis AEFIs
Events occurring in cluster
21. Channels and Timeline Sub Center / Outreach
for Reporting Serious
AEFI cases
Private District
PHC/CHC
Practitioner Hospital,
Med college
FIR to Distt HQ within 24 hrs or Other
Institutions
District
FIR forwarded within next 24 hrs
PIR with available med record within 7 days
State DIR & all med records within 3 months
MOHFW
Govt of India
State drug controller) State EPI officer
Vaccine
Asst Comm (UIP) DCG (India)
Manufacturer
22. Pending Documents - AEFI - West Bengal
Serial Post
N Mortem Vaccine
o EPID No District Patient's name FIR PIR DIR report Samples
1 WB-SPG-11-001 South 24 PGS Harun AL Rashid Yes Yes Pending
Paschim
2 WB-MNP-11-003 Midnapore SK Riyazul Yes Pending Pending Pending
3 Sofiya Mondal Yes Pending Pending
4 Antara Siddya Yes Pending Yes
5 Anisha Khatoon Yes Yes Pending
6 WB-MLD-11-001 Malda Puja Chowdhury Yes Yes Pending
7 Tisha Roy Yes Pending Pending
8 WB-MLD-11-002 Malda Saheb SK Yes Pending Pending
9 WB-MLD-11-003 Malda Tahasina Khatoon Yes Yes Pending Pending
10 WB-PRL-11-001 Purulia Prabin Mahato Yes Yes Pending Pending
11 WB-SPG-11-004 South 24 PGS Nurnabi Purkait Yes Yes Pending
12 WB-SPG-11-005 South 24 PGS Mamoni Laskar Yes Yes Pending
13 WB-SPG-11-006 South 24 PGS Alamin Laskar Yes Yes Pending
14 WB_SPG-11-003 South 24 PGS Ajmira Khatoon Yes Yes Pending
15 WB-SPG-11-007 South 24 PGS Habibul SK Yes Yes Pending
16 WB-SPG-11-008 South 24 PGS Raihan Yes Yes Pending
17 SK Irfan Yes Yes Pending
23. Pending Documents - AEFI - West Bengal
Post
Mortem Vaccine
Serial No EPID No District Patient's name FIR PIR DIR report Samples
18 WB-SPG-11-012 South 24 PGS Puja Sarder Yes Pending Pending
19 WB-SPG-11-011 South 24 PGS Amit Mondal Yes Pending Pending
20 WB-HGL-11- Hooghly Raju Saha Yes Pending Pending
21 WB-HGL-11- Hooghly Joy Bag Yes Pending Pending
22 Asmina Khatoon Yes Yes Pending Pending
23 WB-SPG-11-013 South 24 PGS Masud Rahaman Molla Yes Pending Pending
24 WB-MLD-11--004 Malda Hasina Yasmin Yes Yes Pending
25 Tania sardar Yes Pending Pending
26 WB-SPG-11-014 South 24 PGS Sounem Mondal Yes Pending Pending
27 WB-SPG-11-016 South 24 PGS Sasadhar Mondal Yes Pending Pending
28 WB-PRL-11-002 Purulia Nagesh Gorai Yes Yes Pending
29 WB-PRL-11-003 Purulia Shibam Choubey Yes Pending Pending
30 jayashree Ray Yes Pending Pending
31 WB-MLD-11-001 Malda Pabitra Mudi Yes Yes Pending
32 WB-PRL-12-001 Purulia Laxmi Kalindi Yes Pending Pending
33 WB-PRL-12-002 Purulia Sudip mahato Yes Pending Pending Pending
34 Tamim Molla Yes Pending Pending
27. Investigating AEFIs
• The focus of the investigation should be to confirm the working hypothesis.
• Request laboratory testing only on a clear suspicion and not as routine, and
never before the working hypothesis has been formulated
• Laboratory testing may sometimes confirm or rule out the suspected cause.
• The vaccine and diluent may be tested for sterility and chemical composition;
and the needles and syringe for sterility.
• Send unopened vaccine vials and matching diluent of the same batch for
testing
• Send vaccine samples for testing to the National Control Laboratory (NCL),
Central Research Institute, Kasauli accompanied with a completed Lab
Requisition Form (LRF) along with a copy of the available FIR/PIR. Send the
samples in cold chain (+20C to +80C) and by fastest means.
28. AEFI SAMPLES RECEIVED BY CDL
Commissioner/
Deputy Drug Inspectors
Commissioner /
Assistant
Commissioner
AEFI
State Drug
CMO/DHO Controller/ADC
28
29. Labeling of Vaccine Samples
• Vaccine samples are packed properly
along with “Seal”.
• Same “Seal” is put on the forwarding
letter and on the Thermocol Box.
29
30. Minimum Quantity of AEFI
Samples Required for Testing
• DTP Group of Vaccines - 10 dose x 10 vials or
- 01 dose x 30 vials
• BCG Vaccine -10/20 dose x 40 vials
• Oral Polio Vaccine -20 dose x 10 vials
• Measles/MMR Group -01 dose x 20 vials or
-05 doses x 15 vials or
-10 Dose x 10 Vials
• J.E & Hepatitis vaccines -01 Dose x 30 Vials or
-05 Dose x 15 Vials or
-10 Dose x 10 Vials
30
32. Shipment of Vaccine Samples
• Samples of Vaccines involved in AEFI Cases must be
transported
• With a Formal Letter stating the purpose/Form as per Drug
Act
• In properly Sealed and Addressed containers
• Under Adequate COLD CHAIN (No Freezing, except for
vaccines which are stored at < -20C e.g. Oral Polio Vaccine)
• Preferably by COURIER (On Dot, DTDC)/ In Person
• In Appropriate Quantity (Refer previous text)
• With Relevant Documents enclosed
32
33. Kindly Check
• The labels must never be wrapped with adhesive tape.
• The samples must be so packed that the vials do not get
wet and labels are not peeled off
• Most of the times due to either inadequate number of
samples or no response to NCL’s (National Control
Laboratory) queries the cases are considered as closed.
• Please ensure that the appropriate diluents accompany
the freeze dried vaccines
33
34. Kasauli Lab contact details
Head, Central Drugs Lab.
Central Research Institute
Kasauli – 173204.
Himachal Pradesh.
Email : nclkasauli@bsnl.in
Phone: 0179-2272046, 2272060
Fax: 0179-2272049, 2272016
34
35. CDL Kolkata Lab
The Director
3, KYD Street
Kolkata-700016
Phone: 033-22299021, 22870513
Email: cdlkol@gmail.com
35
36. Where to send samples for testing
used / unused batch of National control lab
vaccine/diluents Kasauli
used / unused batch of CDL Kolkata
syringes/Vit A
Biological products Labs approved
(blood, CSF etc) by State/ Distt
Autopsy (post mortem)
State Forensic Labs
samples
As per information from FDA office
37. Key reasons for under reporting
• Fear/ apprehension to report.
• Unaware about reporting system & process.
• No technical committee to respond.
• Not considering the event as related to
immunization
• Guilt about having caused harm and being
responsible
• Media fear
• A nil report is also important.
38. AEFIs
• Encourage Field workers to report AEFIs without
fear of penalty.
• The aim is to improve systems to prevent /
minimize further AEFI and not to blame
individuals.
39. Roles and Responsibilities
ANMs should:
• Ask the beneficiaries to wait for half an hour after vaccination to
observe for any AEFI.
• Leave the list of children vaccinated in a session with the AWW/ASHA
and request them to be alert and report AEFIs. Share contact details of
self and PHC.
• Treat mild symptoms like fever, pain
• Report deaths, injection site abscesses and other complications in the
monthly UIP report. A nil report is also important.
• Refer serious cases to MO (PHC) or to appropriate health facility for
prompt treatment.
• Report serious events/ cluster of events immediately to the supervisor/
MO (PHC)/ DIO
• Record the time of opening/ reconstitution of vial on the vial label.
• Communicate with parents and other members of the community
• Assist in investigation of AEFIs
40. Roles and Responsibilities
Health Supervisors should:
• Collect and review reports of AEFIs during their
supervisory visits to immunization session sites/ SC.
• Provide on-the-job training to the field staff on safe
injection practices and reporting.
• Assist the MO in conducting the investigation.
41. Roles and Responsibilities
MO PHC/ CHC should: ANMs should:
• Improve/arrange logistics to prevent AEFI due to program errors.
• Train staff in detecting, managing and reporting of AEFIs
• Manage AEFIs and refer to the higher level, if required.
• Initiate investigation, when required
• Complete case report forms (FIR, PIR and DIR) and inform the DIO
immediately for serious cases and deaths
• Report deaths, injection site abscesses and other complications in
the monthly UIP report. A nil report is also important.
• Supervise all reported AEFI through site visits and give immediate
feedback to health workers.
• Communicate with and share the conclusions and results of
investigation with health workers and the community.
42. Roles and Responsibilities
AT DISTRICT LEVEL:
• Establish district AEFI committee
• Train field staff in managing, investigating and reporting
AEFIs.
• Identify a focal person for investigations.
• Identify a designated spokesperson to address the media
if required
• Coordinate AEFI case management
• Report ALL AEFIs - a nil report is also important.
• Investigate serious AEFIs and deaths with State-level
Investigation Teams
• Send FIR, PIR and DIR of serious AEFIs
43. District AEFI Committee
• CMOH
• DIO
• DFWO
• Dy.CMOH-II (Epidemiologist)
• Microbiologist / Pathologist
• Paediatrician / Physician
• DPHNO
• IAP/IMA Representative
• Assistant Drug Controller
44. State AEFI Committee
• SEPIO
• SRTL-NPSP (East)
• Representative from WBSISC
• Microbiologist / Pathologist
• Paediatrician / Physician
• IAP/IMA Representative
• Representative of Director, Drug Control
45. Media hunts for sensational news
Stick to basic messages
when dealing with media
46. Media Management -AEFI
• Verification of FIR / PIR
• Guessing / speculation to be avoided
• Attempt to cover up to be avoided
• Designated responsible spokesperson (block / district / state) should
talk to media
• Provide a complete / simple account of events
• Compassionate & caring attitude is needed
• Avoid off-hand & disparaging remarks
• Try to convince that despite AEFI, the benefit of vaccination
outweighs the risks